ILLUSTRATE Trial: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==Overview== * Clinical research on torcetrapib stopped because of increased incidence of cardiovascular events as an adver...")
 
No edit summary
Line 13: Line 13:
[[Category:Lipopedia]]
[[Category:Lipopedia]]
[[Category:HDL]]
[[Category:HDL]]
[[Category:Clinical trials]]

Revision as of 23:34, 17 September 2013

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

ILLUSTRATE Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of ILLUSTRATE Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ILLUSTRATE Trial

CDC on ILLUSTRATE Trial

ILLUSTRATE Trial in the news

Blogs on ILLUSTRATE Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for ILLUSTRATE Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

References

  1. Barter PJ, Caulfield M, Eriksson M; et al. (2007). "Effects of torcetrapib in patients at high risk for coronary events". The New England Journal of Medicine. 357 (21): 2109–22. doi:10.1056/NEJMoa0706628. PMID 17984165. Unknown parameter |month= ignored (help)